The Company has also engaged a financial advisory firm to further assist with fundraising efforts. -at the same time- the company is restricted by lender as to who it can issue shares to until 30 April 17.
the Company has been evaluating the prospects of its non-wearable injector customer programs and attempting to negotiate terminations of certain non-wearable injector customer contracts- Teneo Touch gone?
The headquarters has a lien on it but may nett around $15 mil if sold.
Amgen could advance the Jan 18 $15 mil early.
Sanofi could buy in
Chapter 7 could result but I believe an administrator would be appointed and assets sold off.
Who ends up with those assets I do not know.
Chapter 11 seems more likely with Orbimed funding but the company could put to the courts and restructure all contracts and I am thinking Sanofi won't come out of this too well.
I believe this will consume the courts for years if SH are shafted.
All IMO
UNS Price at posting:
0.5¢ Sentiment: Hold Disclosure: Held
